220 related articles for article (PubMed ID: 28898400)
1. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006
[TBL] [Abstract][Full Text] [Related]
3. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
[TBL] [Abstract][Full Text] [Related]
4. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M
Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738
[TBL] [Abstract][Full Text] [Related]
5. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
6. Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer.
Zaza MMA; Salem TAE; El-Sadat AM; Hassan Ali M
Urologia; 2024 Feb; 91(1):61-68. PubMed ID: 37905506
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes.
Li H; Wang L; Li H; Zhang P; Li Z; Xue L; Wang Z; Fu D; Chen Q; Luo Q; Chong T; Wang Z
Oncology; 2024; 102(4):337-342. PubMed ID: 37647883
[TBL] [Abstract][Full Text] [Related]
8. Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
You C; Li Q; Qing L; Li R; Wang Y; Cheng L; Dong Z
Int Urol Nephrol; 2024 Jan; 56(1):103-120. PubMed ID: 37659995
[TBL] [Abstract][Full Text] [Related]
9. Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer.
Lai LY; Tafuri SM; Ginier EC; Herrel LA; Dahm P; Maisch P; Lane GI
Cochrane Database Syst Rev; 2022 Apr; 4():CD014887. PubMed ID: 35393644
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.
Rahman ZA; Hidayatullah F; Lim J; Hakim L
Arch Ital Urol Androl; 2024 Feb; 96(1):12154. PubMed ID: 38363237
[TBL] [Abstract][Full Text] [Related]
11. Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: A retrospectively clinical study.
Wang S; Yu Z; Du P; Cao Y; Yang X; Ma J; Tang X; Zhang Q; Yang Y
Asia Pac J Clin Oncol; 2024 Apr; 20(2):228-233. PubMed ID: 36656047
[TBL] [Abstract][Full Text] [Related]
12. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
Abou Chakra M; Packiam VT; Duquesne I; Peyromaure M; McElree IM; O'Donnell MA
Expert Opin Pharmacother; 2024 Feb; 25(2):203-214. PubMed ID: 38264853
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
Necchi A; Roumiguié M; Kamat AM; Shore ND; Boormans JL; Esen AA; Lebret T; Kandori S; Bajorin DF; Krieger LEM; Niglio SA; Uchio EM; Seo HK; de Wit R; Singer EA; Grivas P; Nishiyama H; Li H; Baranwal P; Van den Sigtenhorst-Fijlstra M; Kapadia E; Kulkarni GS
Lancet Oncol; 2024 Jun; 25(6):720-730. PubMed ID: 38740030
[TBL] [Abstract][Full Text] [Related]
14. Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.
Kobayashi M; Fujiyama N; Tanegashima T; Narita S; Yamamoto Y; Fujimoto N; Ueda S; Takeuchi A; Numakura K; Habuchi T; Matsuyama H; Eto M; Shiota M
Cancer Immunol Immunother; 2022 Mar; 71(3):727-736. PubMed ID: 34379177
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
Massari M; O'Malley P; Benidir T; Su LM; Gao H; Crispen PL
Urol Oncol; 2024 May; ():. PubMed ID: 38802293
[TBL] [Abstract][Full Text] [Related]
16. Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin.
Trépanier G; Nykopp T; Rosebush-Mercier R; Gris T; Fadel J; Black PC; Toren P
Clin Genitourin Cancer; 2024 Apr; 22(2):354-359.e1. PubMed ID: 38185610
[TBL] [Abstract][Full Text] [Related]
17. Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ.
McElree IM; Mott SL; Hougen HY; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jul; 42(7):221.e9-221.e16. PubMed ID: 38609747
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.
Thomas DE; Kaimakliotis HZ; Rice KR; Pereira JA; Johnston P; Moore ML; Reed A; Cregar DM; Franklin C; Loman RL; Koch MO; Bihrle R; Foster RS; Masterson TA; Gardner TA; Sundaram CP; Powell CR; Beck SDW; Grignon DJ; Cheng L; Albany C; Hahn NM
Clin Genitourin Cancer; 2017 Aug; 15(4):479-486. PubMed ID: 28040424
[TBL] [Abstract][Full Text] [Related]
19. Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial.
Katims AB; Tallman J; Vertosick E; Porwal S; Dalbagni G; Cha EK; Smith R; Benfante N; Herr HW
JAMA Oncol; 2024 Apr; 10(4):522-525. PubMed ID: 38358761
[TBL] [Abstract][Full Text] [Related]
20. [Transurethral resection of bladder tumors (TURBT)].
Oswald D; Pallauf M; Herrmann TRW; Netsch C; Becker B; Lehrich K; Miernik A; Schöb DS; Sievert KD; Gross AJ; Westphal J; Lusuardi L; Deininger S
Urologe A; 2022 Jan; 61(1):71-82. PubMed ID: 34982181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
